Financial Results, Healthcare Product Launch, Quarterly Dividend, Monthly Metrics, and Presentation Schedule - Research Reports on Lululemon, Kimberly-Clark, American Tower, TD Ameritrade and Aflac

NEW YORK, September 15, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Lululemon Athletica Inc. (NASDAQ: LULU), Kimberly-Clark Corporation (NYSE: KMB), American Tower Corporation (NYSE: AMT), TD Ameritrade Holding Corporation (NYSE: AMTD) and Aflac Inc. (NYSE: AFL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6456-100free.

--
Lululemon Athletica Inc. Research Reports
On September 11, 2014, Lululemon Athletica Inc. (Lululemon) announced its financial results for Q2 FY 2014 (period ended August 3, 2014). Lululemon's net revenue for the quarter increased 13.4% YoY to $390.7 million. Comparable store sales for Q2 FY 2014 decreased by 5% on a constant dollar basis while direct to consumer revenue increased 30% on a constant dollar basis. Q2 FY 2014 diluted EPS for the quarter was $0.33 on net income of $48.7 million, compared to diluted EPS of $0.39 on net income of $56.5 million in Q2 FY 2013. Lululemon informed that for Q3 FY 2014, the Company expects net revenue to be in the range of $420 million to $425 million based on a total comparable sales increase in the low single digits on a constant-dollar basis, while diluted EPS is expected to range between $0.36 and $0.38. The full research reports on Lululemon are available to download free of charge at:

http://www.analystsreview.com/Sep-15-2014/LULU/report.pdf

--
Kimberly-Clark Corporation Research Reports
On September 9, 2014, Kimberly-Clark Corporation's subsidiary Kimberly-Clark Health Care introduced the new soft, lightweight AERO BLUE* Performance Surgical Gown, which offers four times more protection than other comparable surgical gowns. According to the Company, AERO BLUE* features a proprietary fabric with innovative Core technology that delivers the highest fluid protection available in a Level 3 surgical gown as defined by the Association for the Advancement of Medical Instrumentation (AAMI). Alex Hodges, General Manager, Surgical & Infection Prevention, Kimberly-Clark Health Care, said, "Surgical gowns provide a critical level of safety in the OR, but clinicians often feel they must sacrifice comfort for protection. That's why Kimberly-Clark is excited to introduce AERO BLUE* Performance Gowns. With much higher fluid protection and unmatched comfort, AERO BLUE* represents a significant innovation in perioperative protection." The full research reports on Kimberly-Clark are available to download free of charge at:

http://www.analystsreview.com/Sep-15-2014/KMB/report.pdf

--
American Tower Corporation Research Reports
On September 10, 2014, American Tower Corporation (American Tower) announced that its board of directors has declared a quarterly cash distribution of $0.36 per share on its common stock, payable on October 7, 2014 to stockholders of record as on September 23, 2014. Additionally, American Tower's board has declared a cash distribution of c. $1.31 per share on the Company's 5.25% Mandatory Convertible Preferred Stock, Series A, payable on November 17, 2014 to holders of record as on November 1, 2014. The full research reports on American Tower are available to download free of charge at:

http://www.analystsreview.com/Sep-15-2014/AMT/report.pdf

--
TD Ameritrade Holding Corporation Research Reports
On September 10, 2014, TD Ameritrade Holding Corporation (TD Ameritrade) reported monthly metrics for August 2014. According to the Company, its August 2014 activities included - an average of 381,000 client trades per day, which remained almost unchanged on a year-on-year basis and down 6% QoQ; $665.5 billion in total client assets, up 24% YoY and up 3% QoQ. Average spread-based balances of $93.6 billion, up 6% YoY and up 2% QoQ; and average fee-based balances of $143.5 billion, up 17% YoY and essentially flat on QoQ basis. The full research reports on TD Ameritrade are available to download free of charge at:

http://www.analystsreview.com/Sep-15-2014/AMTD/report.pdf

--
Aflac Inc. Research Reports
On September 8, 2014, Aflac Incorporated (Aflac) announced that it will make a presentation at the Tokyo Financial Analysts Briefing on September 15, 2014 at 8:00 p.m. (EDT)/September 16, 2014 at 9:00 a.m. (Tokyo time). According to the Company, the presentations will be available via live webcast at Aflac's website. The full research reports on Aflac are available to download free of charge at:

http://www.analystsreview.com/Sep-15-2014/AFL/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


SOURCE Analysts Review

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.